文献速递新发突发、热带与寄生虫病

在标准防控措施高覆盖率地区大规模给药伊维菌素和双氢青蒿素-哌喹抗疟:冈比亚整群随机对照试验

Mass drug administration of ivermectin and dihydroartemisinin-piperaquine against malaria in settings with high coverage of standard control interventions: a cluster-randomised controlled trial in The Gambia.
PubMed 文献 · Lancet Infect Dis · 2021-12-15

在冈比亚标准疟疾防控措施高覆盖地区开展开放标签整群随机对照试验,32个村庄随机分组,干预组在2018年和2019年两个疟疾传播季每月接受一轮伊维菌素和双氢青蒿素-哌喹大规模给药,共三1轮。2019年11月干预组疟疾患病率5.1%显著低于对照组12.8%(OR 0.30,95%CI 0.16-0.59;p<0.001),但冈比亚按蚊经产率两组无显著差异。干预安全且耐受良好。

要点

  • 标准防控高覆盖地区,伊维菌素联合双氢青蒿素-哌喹大规模给药使疟疾患病率从12.8%降至5.1%(OR 0.30)。
  • 冈比亚按蚊经产率对照组83.1% vs 干预组81.7%(OR 0.90,95%CI 0.66-1.25;p=0.537),无显著差异。
  • 干预安全且耐受良好,11例严重不良事件均与干预无关。

核心结论

  • 在标准防控措施高覆盖地区,伊维菌素和双氢青蒿素-哌喹大规模给药安全且耐受良好,显著降低疟疾患病率;但未观察到伊维菌素对媒介经产率的影响。

研究设计与样本

  • 开放标签、整群随机对照试验,在冈比亚东部上河区开展,村庄按1:1随机分为干预组和对照组各16个。
  • 研究人群共10638人,其中干预村4939人(46%);纳入村庄基线恶性疟原虫患病率7-46%(全年龄)且村间至少间隔3 km。
  • 干预组在2018年8月27日至10月31日和2019年7月15日至9月30日两个疟疾传播季每月接受一轮伊维菌素和双氢青蒿素-哌喹大规模给药,共三轮。
  • 主要结局为2019年11月第二干预年结束时qPCR疟疾患病率和冈比亚按蚊(s l)经产率,按意向治疗人群分析。

主要发现

  • 2019年11月疟疾患病率对照组12.8%(324/2529)vs 干预组5.1%(140/2722),OR 0.30(95%CI 0.16-0.59;p<0.001)。
  • 冈比亚按蚊(s l)经产率对照组83.1%(552/664)vs 干预组81.7%(441/540),OR 0.90(95%CI 0.66-1.25;p=0.537)。
  • 2019年不良事件:第一轮386/3991(9.7%)、第二轮201/3750(5.4%)、第三轮168/3752(4.5%);11例严重不良事件均与干预无关。
  • 双氢青蒿素-哌喹覆盖率2018年为49.0%-58.4%,2019年为76.1%-86.0%;伊维菌素覆盖率2018年为46.9%-52.2%,2019年为71.7%-82.9%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Although the malaria burden has substantially decreased in sub-Saharan Africa, progress has stalled. We assessed whether mass administration of ivermectin (a mosquitocidal drug) and dihydroartemisinin-piperaquine (an antimalarial treatment) reduces malaria in The Gambia, an area with high coverage of standard control interventions. METHODS: This open-label, cluster-randomised controlled trial was done in the Upper River region of eastern Gambia. Villages with a baseline Plasmodium falciparum prevalence of 7-46% (all ages) and separated from each other by at least 3 km to reduce vector spillover were selected. Inclusion criteria were age and anthropometry (for ivermectin, weight of ≥15 kg; for dihydroartemisinin-piperaquine, participants older than 6 months); willingness to comply with trial procedures; and written informed consent. Villages were randomised (1:1) to either the intervention (ivermectin [orally at 300-400 μg/kg per day for 3 consecutive days] and dihydroartemisinin-piperaquine [orally depending on bodyweight] plus standard control interventions) or the control group (standard control interventions) using computer-based randomisation. Laboratory staff were masked to the origin of samples. In the intervention group, three rounds of mass drug administration once per month with ivermectin and dihydroartemisinin-piperaquine were given during two malaria transmission seasons from Aug 27 to Oct 31, 2018, and from July 15 to Sept 30, 2019. Primary outcomes were malaria prevalence by qPCR at the end of the second intervention year in November 2019, and Anopheles gambiae (s l) parous rate, analysed in the intention-to-treat population. This trial is registered with ClinicalTrials.gov, NCT03576313. FINDINGS: Between Nov 20 and Dec 7, 2017, 47 villages were screened for eligibility in the study. 15 were excluded because the baseline malaria prevalence was less than 7% (figure 1). 32 villages were enrolled and randomised to either the intervention or control group (n=16 in each group). The study population was 10 638, of which 4939 (46%) participants were in intervention villages. Coverage for dihydroartemisinin-piperaquine was between 49·0% and 58·4% in 2018, and between 76·1% and 86·0% in 2019; for ivermectin, coverage was between 46·9% and 52·2% in 2018, and between 71·7% and 82·9% in 2019. In November 2019, malaria prevalence was 12·8% (324 of 2529) in the control group and 5·1% (140 of 2722) in the intervention group (odds ratio [OR] 0·30, 95% CI 0·16-0·59; p<0·001). A gambiae (s l) parous rate was 83·1% (552 of 664) in the control group and 81·7% (441 of 540) in the intervention group (0·90, 0·66-1·25; p=0·537). In 2019, adverse events were recorded in 386 (9·7%) of 3991 participants in round one, 201 (5·4%) of 3750 in round two, and 168 (4·5%) of 3752 in round three. None of the 11 serious adverse events were related to the intervention. INTERPRETATION: The intervention was safe and well tolerated. In an area with high coverage of standard control interventions, mass drug administration of ivermectin and dihydroartemisinin-piperaquine significantly reduced malaria prevalence; however, no effect of ivermectin on vector parous rate was observed. FUNDING: Joint Global Health Trials Scheme. TRANSLATION: For the French translation of the abstract see Supplementary Materials section.

来源:Lancet Infect Dis,查看原文。版权归原作者所有。

引用

  1. Dabira ED, Soumare HM, Conteh B, et al. Mass drug administration of ivermectin and dihydroartemisinin-piperaquine against malaria in settings with high coverage of standard control interventions: a cluster-randomised controlled trial in The Gambia. Lancet Infect Dis. 2021. PMID: 34919831. doi:10.1016/S1473-3099(21)00557-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。